Menu Search
Equities

Biosenic SA

BT1:DEU

Biosenic SA

Actions
  • Price (EUR)0.015
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-83.70%
  • Beta--
Data delayed at least 15 minutes, as of May 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biosenic SA formerly known as Bone Therapeutics SA is a Belgium-based company developing cell therapy products. The Company develops cell therapy products for the treatment and regeneration of bone tissue and bone reconstruction applications, osteonecrosis, ununited fractures, and maxillo-facial reconstruction. It is engaged in research, enable adult stem cell isolation, expansion, and osteogenic differentiation. The Company’s therapeutic area focus is bone diseases, with extensions to joint, mainly osteoarthritis and disc degeneration. It also provides cell therapy platform for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO (Arsenic trioxide/ Oral arsenic trioxide).

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-19.67m
  • Incorporated2006
  • Employees12.00
  • Location
    Biosenic SARue Granbonpre 11, Batiment H (bte 24)MONT-SAINT-GUIBERT 1435BelgiumBEL
  • Phone+32 493097366
  • Fax+32 71121001
  • Websitehttp://www.bonetherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.